新医学2025，Vol.56Issue(6)：553-559,7.DOI:10.12464/j.issn.0253-9802.2025-0156
新型体重管理药物与减重代谢手术的角色再思考
Revisiting the role of novel weight management medications and bariatric surgery
摘要
Abstract
The global prevalence of obesity has continued to rise globally over the past two decades.Obesity is closely associated with increased risk of metabolic,cardiovascular,and other diseases,reduced quality of life and shortened life expectancy.Bariatric surgery is recognized as a highly effective weight loss measure,with studies showing its effects lasting more than 10 years.Moreover,bariatric surgery not only leads to weight loss but also improves cardiovascular and metabolic risk factors,such as type 2 diabetes,hypertension,and dyslipidaemia.It also demonstrates sound therapeutic effects on other obesity-related diseases,such as polycystic ovary syndrome(PCOS),sleep apnea,and osteoarthritis.Studies have shown that patients undergoing bariatric surgery have reduced all-cause mortality,cardiovascular events and cancer risk.The emergence of glucagon-like peptide-1 receptor agonist therapies(GLP-1 RA,semaglutide)and GLP-1/GIP dual receptor agonist(tirzepatide)has demonstrated significant weight loss effects with continuous use.Similar to bariatric surgery,these drugs can improve outcomes for type 2 diabetes,cardiovascular mortality,and other obesity-related complications.The article compares bariatric surgery with enteral proinsulin agonists in terms of weight loss efficacy,complication rates,risk profile,cost-effectiveness,and accessibility,explores the value and promise of these popular drugs and bariatric surgery in the treatment of obesity.关键词
减重外科/GLP-1受体激动剂/肠促胰岛素/司美格鲁肽/替尔泊肽/肥胖Key words
Bariatric surgery/GLP-1 receptor agonists/Incretin/Semaglutide/Tirzepatide/Obesity引用本文复制引用
梁辉..新型体重管理药物与减重代谢手术的角色再思考[J].新医学,2025,56(6):553-559,7.基金项目
江苏省科教能力提升工程/江苏省医学重点学科建设基金(ZDXK202222) （ZDXK202222）
